{"success":true,"data":{"pressRelease":{"id":"134367","rtpr_id":"nGNX3vyDph","ticker":"SCTX","exchange":"NASDAQ","all_tickers":["SCTX"],"title":"Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights","author":"Globe Newswire","published_at":"2026-09-02T20:05:00.958Z","article_body":"Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering\ntherapy powered by ELXR, a highly engineered epigenetic silencing technology\ndesigned to deliver ultra-long-acting cholesterol lowering without permanent\ngenetic changes\n\nAwarded more than $25 million from the California Institute for Regenerative\nMedicine (CIRM) to advance both STX-1200 for Lp(a) lowering and STX-1400 for\ntriglyceride lowering toward clinical entry\n\nCompleted upsized initial public offering, including full exercise of the\nunderwriters’ purchase option, and a concurrent private placement to Sanofi,\ngenerating approximately $155.5 million in aggregate gross proceeds\n\nCash, cash equivalents, and marketable securities of $43.0 million as of June\n30, 2026, plus approximately $140.6 million of net proceeds raised from the\nJuly 2026 IPO and concurrent private placement, provides funding into the\nfirst half of 2029\n\nALAMEDA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc.\n(“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a\nclinical-stage biotechnology company engineering purpose-built in vivo CRISPR\ntechnologies designed to extend healthy lifespan through disease prevention\nand durable therapeutic intervention, today reported financial results for the\nsecond quarter ended June 30, 2026, and provided recent corporate and pipeline\nupdates.\n\n“The second quarter and the weeks immediately following represented a\ntransformational period for Scribe,” said Benjamin Oakes, Ph.D., co-founder\nand Chief Executive Officer of Scribe Therapeutics. “We advanced our lead\nsilencing asset STX-1150 into the clinic, secured significant grant support\nfrom CIRM to develop our next two cardiometabolic assets, and successfully\ncompleted our initial public offering. These achievements position us to\nexecute across a broadly differentiated portfolio of CRISPR genetic medicines\ndesigned to address the three major lipid drivers of atherosclerotic\ncardiovascular disease: LDL-C, Lp(a), and triglycerides. Our purpose-built\ntechnologies are uniquely poised to democratize access to the cardioprotective\neffects of beneficial human genetics. Guided by nature's blueprint for\nimproved cardiovascular health, our aim is to shift the treatment paradigm of\nheart disease from chronic intervention of symptoms toward durable disease\nprevention and lifespan extension.”\n\nPipeline Highlights\n\nSTX-1150: In vivo epigenetic silencing therapy for LDL-C lowering\n* Initiated first-in-human Phase 1 clinical trial in Australia for Scribe’s\nepigenetic silencing therapy STX-1150.   * STX-1150 utilizes our Epigenetic\nLong-term X Repressor (ELXR) and is designed as a liver-targeted, in vivo\nCRISPR-based epigenetic silencing therapy that represses PCSK9, a genetically\nand clinically validated target for LDL-C lowering, without permanently\naltering the underlying DNA sequence.\n\n* The Phase 1 study, initiated in mid-2026, will evaluate the safety,\ntolerability, and efficacy of STX-1150 in adults with elevated low-density\nlipoprotein cholesterol (LDL-C) and increased risk of atherosclerotic\ncardiovascular disease (ASCVD).\n\n  \n* Presented late-breaking data at the European Atherosclerosis Society (EAS)\nCongress supporting STX-1150 for persistent LDL-C lowering after a single\ndose.  * In non-human primates (NHPs), a single administration of an STX-1150\nELXR prototype demonstrated PCSK9 silencing of up to 90%, leading to LDL-C\nreductions of up to 68%.\n* A therapeutically relevant dose of 0.75 mg/kg produced durable LDL-C\nreductions of greater than 50%, sustained for two years, with liver enzyme\nprofiles comparable to saline controls.\n* A toxicology study in NHPs showed no adverse clinical observations.\n\n  \n* Epigenetic silencing with STX-1150 is designed to address a major limitation\nof current LDL-C lowering approaches and is positioned to recapitulate the\ncardioprotective effects of human genetics.  * Current LDL-C therapies remain\nlimited by adherence and durability: recent studies show 50 to 70% of patients\ndiscontinue LDL-C-lowering medicine within one year, increasing heart attack\nrisk, while evidence indicates lifelong and earlier LDL-C lowering can deliver\nsubstantially greater ASCVD risk reduction than late or inadequate treatment.\n* STX-1150 is designed to overcome this gap by using ELXR, Scribe’s highly\nengineered epigenetic silencing technology, to down-regulate PCSK9\ntranscription and deliver persistent, potent LDL-C reductions for years\nwithout permanently altering DNA.\n* STX-1150 aims to mimic the protective cardiovascular profile seen in people\nwith naturally occurring PCSK9 loss-of-function variants, who can have a 28%\nlower mean LDL-C, with up to 88% lower coronary heart disease risk. By doing\nso, STX-1150 should help shift LDL-C management from burdensome chronic\ntreatment toward durable, long-term prevention.\n  \n* Clinical data expected in the first half of 2027.  * Scribe anticipates\nreporting initial clinical data, including safety, tolerability, and LDL-C\nlowering activity, from the single ascending dose (SAD) portion of the\nSTX-1150 Phase 1 trial in the first half of 2027.\nSTX-1200 and STX-1400: Advancing cardiometabolic gene editing programs\ntargeting genetically driven, severely elevated Lp(a) and triglycerides,\nrespectively. Awarded approximately $25.7 million in combined non-dilutive\nCIRM grants.\n* Awarded $12.7 million for advancing STX-1200 toward clinical entry as early\nas 2027.   * STX-1200 targets LPA utilizing X-Editor (XE), Scribe’s highly\nengineered genetic editing technology. STX-1200 is designed to lower\nlipoprotein(a) (Lp(a)) in patients with genetically elevated Lp(a) and\nassociated ASCVD risk. In preclinical studies, STX-1200 surrogates achieved\ngreater than 95% Lp(a) reduction in NHPs.  \n  \n* Awarded $13.0 million for advancing STX-1400 toward clinical entry as early\nas 2027.   * STX-1400 targets APOC3 utilizing XE. STX-1400 is designed to\nlower triglyceride-rich lipoproteins and address the risk of acute\npancreatitis in severe hypertriglyceridemia, including familial\nchylomicronemia syndrome and multifactorial chylomicronemia syndrome. In\npreclinical studies, STX-1400 surrogates achieved greater than 75% on-target\nAPOC3 editing in NHPs.\nPlatform and Scientific Leadership\n\nPublished updated findings in bioRxiv\n(https://www.globenewswire.com/Tracker?data=qna4_l-HXUjv1VH9ZGLcNJNLQ29Kk2FOfFe8J6PnZZdQh7YItOTjsQ5hMQqvFUYLR-jZzj8buenDJ0IJmBrmQSD45izVAQWCTrU2P26pzPu7yA2GvUVxFlJrPXmbsOkTfSlCkqrv8mAErb_AGVg-2SykKKtvcoR-indzjc6cnvM=),\nhighlighting the ELXR platform's novel enhancements in potency and safety\nenabling the durable repression of target genes without permanent DNA\nmodification.\n* The publication illustrates a novel framework for engineering context-aware\nepigenetic therapies.\n* Further demonstrated that these engineering approaches developed molecules\nthat decrease off-targets by up to 10x and increase on-target activity across\nloci as much as 4x.\n* To the Company's knowledge, this is the first example of an epigenetic\ntherapy with an allosterically gated sequential proofreading mechanism that\nmeaningfully widens the therapeutic window of CRISPR approaches.\nCorporate Highlights\n* Nasdaq listing. Common stock began trading on the Nasdaq Global Market on\nJuly 24, 2026, under the ticker symbol “SCTX.” Scribe upsized its initial\npublic offering and priced at the high end of the range at $15.00 per share.\nThe Company also completed a concurrent private placement to Sanofi at the IPO\nprice.\n* Approximately $155.5 million in aggregate gross proceeds. Capital raised\nfrom the IPO, the full exercise of the underwriters’ option, and the\nconcurrent private placement totaled $155.5 million before underwriting\ndiscounts, commissions, and offering expenses.\n* Funding into the first half of 2029. Based on Scribe’s current operating\nplan, the Company believes its existing cash, cash equivalents, and\ninvestments, together with net proceeds from the IPO and the concurrent\nprivate placement, will be sufficient to fund its operating expenses and\ncapital expenditure requirements into the first half of 2029.\nSecond Quarter 2026 Financial Results\n* Cash position: Cash, cash equivalents, and marketable securities were $43.0\nmillion as of June 30, 2026, compared with $58.0 million as of December 31,\n2025. Cash, cash equivalents, and marketable securities of $43.0 million as of\nJune 30, 2026, plus approximately $140.6 million of net proceeds raised from\nthe July 2026 IPO and concurrent private placement, provides funding into the\nfirst half of 2029.\n* Collaboration revenue: Collaboration revenue was $1.9 million for the three\nmonths ended June 30, 2026, compared with $4.9 million for the prior year\nperiod in 2025. The decrease was primarily attributable to lower reimbursable\nresearch and development activities and reduced revenue recognition under the\nCompany's collaboration arrangements.\n* Research and development expenses: Research and development expenses were\n$8.8 million for the three months ended June 30, 2026, compared with $13.9\nmillion for the prior year period in 2025. The decrease was primarily\nattributable to lower personnel-related costs and reduced spending on\npreclinical research programs, partially offset by increased expenditures\nsupporting the advancement of the STX-1150 Phase 1 clinical trial, including\nclinical and manufacturing activities.\n* General and administrative expenses: General and administrative expenses\nwere $2.5 million for the second quarter of 2026, compared with $2.6 million\nfor the second quarter of 2025. The decrease was primarily attributable to\nlower administrative costs.\n* Net loss: Net loss was $6.5 million, or $2.62 per basic and diluted share,\nfor the three months ended June 30, 2026, compared with a net loss of $9.9\nmillion, or $4.08 per basic and diluted share, for the same period in 2025.\nAbout Scribe Therapeutics Inc.\nScribe Therapeutics is a clinical-stage biotechnology company engineering\nCRISPR-based technologies into purpose-built in vivo genetic medicines\ndesigned to become standard of care treatments for patients suffering from\nhighly prevalent diseases, starting with cardiometabolic disease. Leveraging\nits CRISPR by Design™ approach and nature’s blueprint for improved\ncardiovascular health, Scribe’s initial programs focus on addressing the key\ndrivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides.\nThe company’s lead candidate, STX-1150, is a novel liver-targeted therapy\ndesigned to epigenetically silence the PCSK9 gene and reduce LDL-C levels\nwithout inducing permanent DNA changes. To broaden and accelerate the impact\nof its engineered CRISPR technologies for patients, Scribe has formed\nstrategic collaborations with world-leading pharmaceutical companies including\nSanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and\nbacked by leading life sciences investors, Scribe is advancing scalable,\ntransformative, and preventative genetic medicines with the goal of improving\noutcomes and democratizing access to the protective effects of beneficial\nhuman genetics. To learn more, visit www.scribetx.com.\n\nForward-Looking Statements\nThis press release contains “forward-looking statements” within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995. All statements other than statements of\nhistorical fact contained in this press release, including statements\nregarding Scribe’s strategy, business plans and objectives; the therapeutic\npotential, safety, efficacy, durability, scalability and clinical or\ncommercial prospects of Scribe’s product candidates and technologies; the\ndesign, initiation, enrollment, conduct, timing and results of preclinical\nstudies and clinical trials; the timing of clinical data and other anticipated\nmilestones; the advancement of STX-1150, STX-1200, STX-1400 and other\nprograms; the expected use and benefits of CIRM funding; and Scribe’s\nexpected cash runway and financial position are forward-looking statements.\nThe words “aim,” “anticipate,” “believe,” “continue,”\n“could,” “design,” “estimate,” “expect,” “goal,”\n“intend,” “may,” “plan,” “potential,” “seek,”\n“should,” “target,” “will” and similar expressions are intended to\nidentify forward-looking statements, although not all forward-looking\nstatements contain these identifying words.\n\nForward-looking statements are based on management’s current expectations\nand assumptions and are subject to risks and uncertainties that could cause\nactual results to differ materially from those expressed or implied by such\nstatements. These risks and uncertainties include those described under the\nheading “Risk Factors” in Scribe’s filings with the U.S. Securities and\nExchange Commission, including its final prospectus filed pursuant to Rule\n424(b)(4) under the Securities Act of 1933, as amended, and future reports\nthat Scribe may file with the SEC. Except as required by law, Scribe\nundertakes no obligation to update any forward-looking statements contained\nherein to reflect events or circumstances after the date hereof or to reflect\nnew information or the occurrence of unanticipated events.\n\nInvestor Contact:\nInvestor Relations, Scribe Therapeutics\nir@scribetx.com\n\nMedia Contact:\nThermal for Scribe Therapeutics\nmedia@scribetx.com\n\n                                                                                                                                                   \n SCRIBE THERAPEUTICS INC.                                                                                                                          \n Statement of Operations                                                                                                                           \n (in thousands, except share and per share data)                                                                                                   \n (Unaudited)                                                                                                                                       \n                                                                                                                                                   \n                                                  Three Months Ended June 30,                      Six Months Ended June 30,                       \n                                                                \n                                                  2026                      2025                   2026                       2025                 \n Collaboration revenue                            $     1,918               $     4,898            $     4,151                $     22,023         \n Operating expenses:                                                                                                                               \n Research and development                               8,823                     13,884                 20,128                     29,876         \n General and administrative                             2,490                     2,641                  5,844                      9,332          \n Total operating expenses                               11,313                    16,525                 25,972                     39,208         \n Loss from operations                                   (9,395  )                 (11,627  )             (21,821  )                 (17,185  )     \n Interest income and other income (expense), net        383                       880                    898                        1,944          \n Interest expense                                       (276    )                 (598     )             (875     )                 (1,197   )     \n Change in fair value of Convertible Note               3,023                     730                    (1,585   )                 2,083          \n Net loss before provision for income taxes             (6,265  )                 (10,615  )             (23,383  )                 (14,355  )     \n Provision for income tax                               (212    )                 712                    (441     )                 1,027          \n Net loss                                         $     (6,477  )           $     (9,903   )       $     (23,824  )           $     (13,328  )     \n\n\n\n SCRIBE THERAPEUTICS INC.                                                              \n Selected Balance Sheet Items                                                          \n (in thousands, except share and per share data)                                       \n (Unaudited)                                                                           \n                                         June 30,              December 31,            \n                                         2026                  2025                    \n                                                                                       \n Cash, cash equivalents and investments  $    43,009           $      57,963           \n Total Assets                                 57,927                  78,219           \n Total Liabilities                            102,417                 101,282          \n Total stockholders' deficit                  (164,846  )             (143,419  )      \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/aa20814a-db77-4391-99ce-f0f195ba207c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3vyDph","title":"Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights","author":"Globe Newswire","ticker":"SCTX","created":"2026-09-02T20:05:00.958Z","tickers":["SCTX"],"exchange":"NASDAQ","article_body":"Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering\ntherapy powered by ELXR, a highly engineered epigenetic silencing technology\ndesigned to deliver ultra-long-acting cholesterol lowering without permanent\ngenetic changes\n\nAwarded more than $25 million from the California Institute for Regenerative\nMedicine (CIRM) to advance both STX-1200 for Lp(a) lowering and STX-1400 for\ntriglyceride lowering toward clinical entry\n\nCompleted upsized initial public offering, including full exercise of the\nunderwriters’ purchase option, and a concurrent private placement to Sanofi,\ngenerating approximately $155.5 million in aggregate gross proceeds\n\nCash, cash equivalents, and marketable securities of $43.0 million as of June\n30, 2026, plus approximately $140.6 million of net proceeds raised from the\nJuly 2026 IPO and concurrent private placement, provides funding into the\nfirst half of 2029\n\nALAMEDA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc.\n(“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a\nclinical-stage biotechnology company engineering purpose-built in vivo CRISPR\ntechnologies designed to extend healthy lifespan through disease prevention\nand durable therapeutic intervention, today reported financial results for the\nsecond quarter ended June 30, 2026, and provided recent corporate and pipeline\nupdates.\n\n“The second quarter and the weeks immediately following represented a\ntransformational period for Scribe,” said Benjamin Oakes, Ph.D., co-founder\nand Chief Executive Officer of Scribe Therapeutics. “We advanced our lead\nsilencing asset STX-1150 into the clinic, secured significant grant support\nfrom CIRM to develop our next two cardiometabolic assets, and successfully\ncompleted our initial public offering. These achievements position us to\nexecute across a broadly differentiated portfolio of CRISPR genetic medicines\ndesigned to address the three major lipid drivers of atherosclerotic\ncardiovascular disease: LDL-C, Lp(a), and triglycerides. Our purpose-built\ntechnologies are uniquely poised to democratize access to the cardioprotective\neffects of beneficial human genetics. Guided by nature's blueprint for\nimproved cardiovascular health, our aim is to shift the treatment paradigm of\nheart disease from chronic intervention of symptoms toward durable disease\nprevention and lifespan extension.”\n\nPipeline Highlights\n\nSTX-1150: In vivo epigenetic silencing therapy for LDL-C lowering\n* Initiated first-in-human Phase 1 clinical trial in Australia for Scribe’s\nepigenetic silencing therapy STX-1150.   * STX-1150 utilizes our Epigenetic\nLong-term X Repressor (ELXR) and is designed as a liver-targeted, in vivo\nCRISPR-based epigenetic silencing therapy that represses PCSK9, a genetically\nand clinically validated target for LDL-C lowering, without permanently\naltering the underlying DNA sequence.\n\n* The Phase 1 study, initiated in mid-2026, will evaluate the safety,\ntolerability, and efficacy of STX-1150 in adults with elevated low-density\nlipoprotein cholesterol (LDL-C) and increased risk of atherosclerotic\ncardiovascular disease (ASCVD).\n\n  \n* Presented late-breaking data at the European Atherosclerosis Society (EAS)\nCongress supporting STX-1150 for persistent LDL-C lowering after a single\ndose.  * In non-human primates (NHPs), a single administration of an STX-1150\nELXR prototype demonstrated PCSK9 silencing of up to 90%, leading to LDL-C\nreductions of up to 68%.\n* A therapeutically relevant dose of 0.75 mg/kg produced durable LDL-C\nreductions of greater than 50%, sustained for two years, with liver enzyme\nprofiles comparable to saline controls.\n* A toxicology study in NHPs showed no adverse clinical observations.\n\n  \n* Epigenetic silencing with STX-1150 is designed to address a major limitation\nof current LDL-C lowering approaches and is positioned to recapitulate the\ncardioprotective effects of human genetics.  * Current LDL-C therapies remain\nlimited by adherence and durability: recent studies show 50 to 70% of patients\ndiscontinue LDL-C-lowering medicine within one year, increasing heart attack\nrisk, while evidence indicates lifelong and earlier LDL-C lowering can deliver\nsubstantially greater ASCVD risk reduction than late or inadequate treatment.\n* STX-1150 is designed to overcome this gap by using ELXR, Scribe’s highly\nengineered epigenetic silencing technology, to down-regulate PCSK9\ntranscription and deliver persistent, potent LDL-C reductions for years\nwithout permanently altering DNA.\n* STX-1150 aims to mimic the protective cardiovascular profile seen in people\nwith naturally occurring PCSK9 loss-of-function variants, who can have a 28%\nlower mean LDL-C, with up to 88% lower coronary heart disease risk. By doing\nso, STX-1150 should help shift LDL-C management from burdensome chronic\ntreatment toward durable, long-term prevention.\n  \n* Clinical data expected in the first half of 2027.  * Scribe anticipates\nreporting initial clinical data, including safety, tolerability, and LDL-C\nlowering activity, from the single ascending dose (SAD) portion of the\nSTX-1150 Phase 1 trial in the first half of 2027.\nSTX-1200 and STX-1400: Advancing cardiometabolic gene editing programs\ntargeting genetically driven, severely elevated Lp(a) and triglycerides,\nrespectively. Awarded approximately $25.7 million in combined non-dilutive\nCIRM grants.\n* Awarded $12.7 million for advancing STX-1200 toward clinical entry as early\nas 2027.   * STX-1200 targets LPA utilizing X-Editor (XE), Scribe’s highly\nengineered genetic editing technology. STX-1200 is designed to lower\nlipoprotein(a) (Lp(a)) in patients with genetically elevated Lp(a) and\nassociated ASCVD risk. In preclinical studies, STX-1200 surrogates achieved\ngreater than 95% Lp(a) reduction in NHPs.  \n  \n* Awarded $13.0 million for advancing STX-1400 toward clinical entry as early\nas 2027.   * STX-1400 targets APOC3 utilizing XE. STX-1400 is designed to\nlower triglyceride-rich lipoproteins and address the risk of acute\npancreatitis in severe hypertriglyceridemia, including familial\nchylomicronemia syndrome and multifactorial chylomicronemia syndrome. In\npreclinical studies, STX-1400 surrogates achieved greater than 75% on-target\nAPOC3 editing in NHPs.\nPlatform and Scientific Leadership\n\nPublished updated findings in bioRxiv\n(https://www.globenewswire.com/Tracker?data=qna4_l-HXUjv1VH9ZGLcNJNLQ29Kk2FOfFe8J6PnZZdQh7YItOTjsQ5hMQqvFUYLR-jZzj8buenDJ0IJmBrmQSD45izVAQWCTrU2P26pzPu7yA2GvUVxFlJrPXmbsOkTfSlCkqrv8mAErb_AGVg-2SykKKtvcoR-indzjc6cnvM=),\nhighlighting the ELXR platform's novel enhancements in potency and safety\nenabling the durable repression of target genes without permanent DNA\nmodification.\n* The publication illustrates a novel framework for engineering context-aware\nepigenetic therapies.\n* Further demonstrated that these engineering approaches developed molecules\nthat decrease off-targets by up to 10x and increase on-target activity across\nloci as much as 4x.\n* To the Company's knowledge, this is the first example of an epigenetic\ntherapy with an allosterically gated sequential proofreading mechanism that\nmeaningfully widens the therapeutic window of CRISPR approaches.\nCorporate Highlights\n* Nasdaq listing. Common stock began trading on the Nasdaq Global Market on\nJuly 24, 2026, under the ticker symbol “SCTX.” Scribe upsized its initial\npublic offering and priced at the high end of the range at $15.00 per share.\nThe Company also completed a concurrent private placement to Sanofi at the IPO\nprice.\n* Approximately $155.5 million in aggregate gross proceeds. Capital raised\nfrom the IPO, the full exercise of the underwriters’ option, and the\nconcurrent private placement totaled $155.5 million before underwriting\ndiscounts, commissions, and offering expenses.\n* Funding into the first half of 2029. Based on Scribe’s current operating\nplan, the Company believes its existing cash, cash equivalents, and\ninvestments, together with net proceeds from the IPO and the concurrent\nprivate placement, will be sufficient to fund its operating expenses and\ncapital expenditure requirements into the first half of 2029.\nSecond Quarter 2026 Financial Results\n* Cash position: Cash, cash equivalents, and marketable securities were $43.0\nmillion as of June 30, 2026, compared with $58.0 million as of December 31,\n2025. Cash, cash equivalents, and marketable securities of $43.0 million as of\nJune 30, 2026, plus approximately $140.6 million of net proceeds raised from\nthe July 2026 IPO and concurrent private placement, provides funding into the\nfirst half of 2029.\n* Collaboration revenue: Collaboration revenue was $1.9 million for the three\nmonths ended June 30, 2026, compared with $4.9 million for the prior year\nperiod in 2025. The decrease was primarily attributable to lower reimbursable\nresearch and development activities and reduced revenue recognition under the\nCompany's collaboration arrangements.\n* Research and development expenses: Research and development expenses were\n$8.8 million for the three months ended June 30, 2026, compared with $13.9\nmillion for the prior year period in 2025. The decrease was primarily\nattributable to lower personnel-related costs and reduced spending on\npreclinical research programs, partially offset by increased expenditures\nsupporting the advancement of the STX-1150 Phase 1 clinical trial, including\nclinical and manufacturing activities.\n* General and administrative expenses: General and administrative expenses\nwere $2.5 million for the second quarter of 2026, compared with $2.6 million\nfor the second quarter of 2025. The decrease was primarily attributable to\nlower administrative costs.\n* Net loss: Net loss was $6.5 million, or $2.62 per basic and diluted share,\nfor the three months ended June 30, 2026, compared with a net loss of $9.9\nmillion, or $4.08 per basic and diluted share, for the same period in 2025.\nAbout Scribe Therapeutics Inc.\nScribe Therapeutics is a clinical-stage biotechnology company engineering\nCRISPR-based technologies into purpose-built in vivo genetic medicines\ndesigned to become standard of care treatments for patients suffering from\nhighly prevalent diseases, starting with cardiometabolic disease. Leveraging\nits CRISPR by Design™ approach and nature’s blueprint for improved\ncardiovascular health, Scribe’s initial programs focus on addressing the key\ndrivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides.\nThe company’s lead candidate, STX-1150, is a novel liver-targeted therapy\ndesigned to epigenetically silence the PCSK9 gene and reduce LDL-C levels\nwithout inducing permanent DNA changes. To broaden and accelerate the impact\nof its engineered CRISPR technologies for patients, Scribe has formed\nstrategic collaborations with world-leading pharmaceutical companies including\nSanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and\nbacked by leading life sciences investors, Scribe is advancing scalable,\ntransformative, and preventative genetic medicines with the goal of improving\noutcomes and democratizing access to the protective effects of beneficial\nhuman genetics. To learn more, visit www.scribetx.com.\n\nForward-Looking Statements\nThis press release contains “forward-looking statements” within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995. All statements other than statements of\nhistorical fact contained in this press release, including statements\nregarding Scribe’s strategy, business plans and objectives; the therapeutic\npotential, safety, efficacy, durability, scalability and clinical or\ncommercial prospects of Scribe’s product candidates and technologies; the\ndesign, initiation, enrollment, conduct, timing and results of preclinical\nstudies and clinical trials; the timing of clinical data and other anticipated\nmilestones; the advancement of STX-1150, STX-1200, STX-1400 and other\nprograms; the expected use and benefits of CIRM funding; and Scribe’s\nexpected cash runway and financial position are forward-looking statements.\nThe words “aim,” “anticipate,” “believe,” “continue,”\n“could,” “design,” “estimate,” “expect,” “goal,”\n“intend,” “may,” “plan,” “potential,” “seek,”\n“should,” “target,” “will” and similar expressions are intended to\nidentify forward-looking statements, although not all forward-looking\nstatements contain these identifying words.\n\nForward-looking statements are based on management’s current expectations\nand assumptions and are subject to risks and uncertainties that could cause\nactual results to differ materially from those expressed or implied by such\nstatements. These risks and uncertainties include those described under the\nheading “Risk Factors” in Scribe’s filings with the U.S. Securities and\nExchange Commission, including its final prospectus filed pursuant to Rule\n424(b)(4) under the Securities Act of 1933, as amended, and future reports\nthat Scribe may file with the SEC. Except as required by law, Scribe\nundertakes no obligation to update any forward-looking statements contained\nherein to reflect events or circumstances after the date hereof or to reflect\nnew information or the occurrence of unanticipated events.\n\nInvestor Contact:\nInvestor Relations, Scribe Therapeutics\nir@scribetx.com\n\nMedia Contact:\nThermal for Scribe Therapeutics\nmedia@scribetx.com\n\n                                                                                                                                                   \n SCRIBE THERAPEUTICS INC.                                                                                                                          \n Statement of Operations                                                                                                                           \n (in thousands, except share and per share data)                                                                                                   \n (Unaudited)                                                                                                                                       \n                                                                                                                                                   \n                                                  Three Months Ended June 30,                      Six Months Ended June 30,                       \n                                                                \n                                                  2026                      2025                   2026                       2025                 \n Collaboration revenue                            $     1,918               $     4,898            $     4,151                $     22,023         \n Operating expenses:                                                                                                                               \n Research and development                               8,823                     13,884                 20,128                     29,876         \n General and administrative                             2,490                     2,641                  5,844                      9,332          \n Total operating expenses                               11,313                    16,525                 25,972                     39,208         \n Loss from operations                                   (9,395  )                 (11,627  )             (21,821  )                 (17,185  )     \n Interest income and other income (expense), net        383                       880                    898                        1,944          \n Interest expense                                       (276    )                 (598     )             (875     )                 (1,197   )     \n Change in fair value of Convertible Note               3,023                     730                    (1,585   )                 2,083          \n Net loss before provision for income taxes             (6,265  )                 (10,615  )             (23,383  )                 (14,355  )     \n Provision for income tax                               (212    )                 712                    (441     )                 1,027          \n Net loss                                         $     (6,477  )           $     (9,903   )       $     (23,824  )           $     (13,328  )     \n\n\n\n SCRIBE THERAPEUTICS INC.                                                              \n Selected Balance Sheet Items                                                          \n (in thousands, except share and per share data)                                       \n (Unaudited)                                                                           \n                                         June 30,              December 31,            \n                                         2026                  2025                    \n                                                                                       \n Cash, cash equivalents and investments  $    43,009           $      57,963           \n Total Assets                                 57,927                  78,219           \n Total Liabilities                            102,417                 101,282          \n Total stockholders' deficit                  (164,846  )             (143,419  )      \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/aa20814a-db77-4391-99ce-f0f195ba207c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-02T20:05:01.119014202Z","server_sent_at_ms":1788379501119},"received_at":"2026-09-02T20:05:01.211Z","source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355504/0/en/scribe-therapeutics-reports-second-quarter-2026-financial-results-and-recent-corporate-highlights.html"},"analysis":{"id":"123259","press_release_id":"134367","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Collaboration revenue declining sharply: Q2 fell to $1.9M from $4.9M, and H1 revenue fell to $4.2M from $22.0M — partnership income is lumpy and shrinking","Total liabilities ($102.4M) exceed total assets ($57.9M) with a $164.8M stockholders' deficit","Pre-revenue clinical-stage model: no product revenue and first human data for lead asset not until H1 2027","Cash runway guidance into H1 2029 is management's projection and assumes execution of the current operating plan"],"eventType":"earnings","narrative":"Scribe Therapeutics posted Q2 2026 collaboration revenue of $1.9 million, down from $4.9 million a year earlier, and narrowed its net loss to $6.5 million, or $2.62 per share, from $9.9 million, or $4.08, in the prior-year quarter.\n\nThe company initiated the first-in-human Phase 1 trial of lead PCSK9-silencing asset STX-1150 in Australia, with initial single-ascending-dose data expected in the first half of 2027, and won roughly $25.7 million in combined CIRM grants to advance STX-1200 (Lp(a) lowering) and STX-1400 (triglyceride lowering) toward clinical entry as early as 2027.\n\nScribe's July 2026 upsized IPO priced at $15.00 per share, plus a concurrent private placement to Sanofi, generated about $155.5 million gross ($140.6 million net), which together with $43.0 million in cash on hand funds operations into the first half of 2029.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Newly listed CRISPR biotech enters the clinic with lead PCSK9 epigenetic silencing asset and a fully funded runway into 2029 — execution phase begins."},"keyFigures":{"revenue":1918000,"drugName":"STX-1150","phaseOfTrial":"Phase 1","offeringPrice":15,"customDimensions":{"net_loss":6477000,"ga_expense":2490000,"cash_runway":"into the first half of 2029","rnd_expense":8823000,"ipo_net_proceeds":140600000,"cirm_grants_total":25700000,"ipo_gross_proceeds":155500000,"cirm_grant_stx_1200":12700000,"cirm_grant_stx_1400":13000000,"net_loss_prior_year":9903000,"cash_position_dec_2025":58000000,"cash_position_jun_2026":43000000,"collaboration_revenue_prior_year":4898000}},"quotedText":"The second quarter and the weeks immediately following represented a\ntransformational period for Scribe","namedEntities":{"people":[{"name":"Benjamin Oakes, Ph.D.","role":"co-founder and CEO"},{"name":"Jennifer Doudna","role":"co-founder and Nobel Prize winner"}],"products":["STX-1150","STX-1200","STX-1400","ELXR (Epigenetic Long-term X Repressor)","X-Editor (XE)","CRISPR by Design"],"companies":[{"name":"Scribe Therapeutics Inc.","ticker":"SCTX","relationship":"filer"},{"name":"Sanofi","relationship":"concurrent private placement investor and strategic collaborator"},{"name":"Eli Lilly","relationship":"strategic collaborator"},{"name":"California Institute for Regenerative Medicine (CIRM)","relationship":"grant provider"}],"dollarAmounts":[{"amount":"$25 million","context":"CIRM awards to advance STX-1200 and STX-1400"},{"amount":"$25.7 million","context":"combined non-dilutive CIRM grants"},{"amount":"$12.7 million","context":"CIRM grant for STX-1200 toward clinical entry"},{"amount":"$13.0 million","context":"CIRM grant for STX-1400 toward clinical entry"},{"amount":"$155.5 million","context":"aggregate gross proceeds from IPO and concurrent Sanofi private placement"},{"amount":"$140.6 million","context":"net proceeds from July 2026 IPO and private placement"},{"amount":"$15.00","context":"IPO price per share"},{"amount":"$43.0 million","context":"cash, cash equivalents and marketable securities as of June 30, 2026"},{"amount":"$58.0 million","context":"cash, cash equivalents and marketable securities as of December 31, 2025"},{"amount":"$1.9 million","context":"Q2 2026 collaboration revenue"},{"amount":"$4.9 million","context":"Q2 2025 collaboration revenue"},{"amount":"$8.8 million","context":"Q2 2026 R&D expenses"},{"amount":"$13.9 million","context":"Q2 2025 R&D expenses"},{"amount":"$2.5 million","context":"Q2 2026 G&A expenses"},{"amount":"$6.5 million","context":"Q2 2026 net loss"},{"amount":"$9.9 million","context":"Q2 2025 net loss"}]},"materialImpact":{"score":3,"reasoning":"Routine Q2 report for a newly listed clinical-stage biotech, but headlined by first-in-human Phase 1 initiation of lead asset STX-1150, ~$25.7M in non-dilutive CIRM grants, and a $155.5M IPO/private placement extending cash runway into H1 2029. Not a binary clinical or regulatory event, so below the 4-5 threshold."},"tickerRelevance":{"others":[],"primary":"SCTX"},"globalImportance":28,"audienceRelevance":24,"eventTypeSecondary":["clinical_trial","offering"],"importanceComponents":{"tickerTier":"small-cap newly IPO'd biotech","eventGravity":"earnings plus Phase 1 initiation plus IPO recap and grant awards","sectorWeight":"high-beta clinical-stage biotech","marketCapAdjustment":"micro/small-cap listing limits broad market impact","retailFavoriteBoost":"CRISPR/Jennifer Doudna name recognition provides modest retail draw"}},"event_type":"earnings","event_type_secondary":["clinical_trial","offering"],"sentiment":"bullish","material_impact_score":3,"narrative":"Scribe Therapeutics posted Q2 2026 collaboration revenue of $1.9 million, down from $4.9 million a year earlier, and narrowed its net loss to $6.5 million, or $2.62 per share, from $9.9 million, or $4.08, in the prior-year quarter.\n\nThe company initiated the first-in-human Phase 1 trial of lead PCSK9-silencing asset STX-1150 in Australia, with initial single-ascending-dose data expected in the first half of 2027, and won roughly $25.7 million in combined CIRM grants to advance STX-1200 (Lp(a) lowering) and STX-1400 (triglyceride lowering) toward clinical entry as early as 2027.\n\nScribe's July 2026 upsized IPO priced at $15.00 per share, plus a concurrent private placement to Sanofi, generated about $155.5 million gross ($140.6 million net), which together with $43.0 million in cash on hand funds operations into the first half of 2029.","key_figures":{"revenue":1918000,"drugName":"STX-1150","phaseOfTrial":"Phase 1","offeringPrice":15,"customDimensions":{"net_loss":6477000,"ga_expense":2490000,"cash_runway":"into the first half of 2029","rnd_expense":8823000,"ipo_net_proceeds":140600000,"cirm_grants_total":25700000,"ipo_gross_proceeds":155500000,"cirm_grant_stx_1200":12700000,"cirm_grant_stx_1400":13000000,"net_loss_prior_year":9903000,"cash_position_dec_2025":58000000,"cash_position_jun_2026":43000000,"collaboration_revenue_prior_year":4898000}},"named_entities":{"people":[{"name":"Benjamin Oakes, Ph.D.","role":"co-founder and CEO"},{"name":"Jennifer Doudna","role":"co-founder and Nobel Prize winner"}],"products":["STX-1150","STX-1200","STX-1400","ELXR (Epigenetic Long-term X Repressor)","X-Editor (XE)","CRISPR by Design"],"companies":[{"name":"Scribe Therapeutics Inc.","ticker":"SCTX","relationship":"filer"},{"name":"Sanofi","relationship":"concurrent private placement investor and strategic collaborator"},{"name":"Eli Lilly","relationship":"strategic collaborator"},{"name":"California Institute for Regenerative Medicine (CIRM)","relationship":"grant provider"}],"dollarAmounts":[{"amount":"$25 million","context":"CIRM awards to advance STX-1200 and STX-1400"},{"amount":"$25.7 million","context":"combined non-dilutive CIRM grants"},{"amount":"$12.7 million","context":"CIRM grant for STX-1200 toward clinical entry"},{"amount":"$13.0 million","context":"CIRM grant for STX-1400 toward clinical entry"},{"amount":"$155.5 million","context":"aggregate gross proceeds from IPO and concurrent Sanofi private placement"},{"amount":"$140.6 million","context":"net proceeds from July 2026 IPO and private placement"},{"amount":"$15.00","context":"IPO price per share"},{"amount":"$43.0 million","context":"cash, cash equivalents and marketable securities as of June 30, 2026"},{"amount":"$58.0 million","context":"cash, cash equivalents and marketable securities as of December 31, 2025"},{"amount":"$1.9 million","context":"Q2 2026 collaboration revenue"},{"amount":"$4.9 million","context":"Q2 2025 collaboration revenue"},{"amount":"$8.8 million","context":"Q2 2026 R&D expenses"},{"amount":"$13.9 million","context":"Q2 2025 R&D expenses"},{"amount":"$2.5 million","context":"Q2 2026 G&A expenses"},{"amount":"$6.5 million","context":"Q2 2026 net loss"},{"amount":"$9.9 million","context":"Q2 2025 net loss"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T20:24:58.560Z","global_importance":28,"audience_relevance":24,"importance_components":{"tickerTier":"small-cap newly IPO'd biotech","eventGravity":"earnings plus Phase 1 initiation plus IPO recap and grant awards","sectorWeight":"high-beta clinical-stage biotech","marketCapAdjustment":"micro/small-cap listing limits broad market impact","retailFavoriteBoost":"CRISPR/Jennifer Doudna name recognition provides modest retail draw"}},"durationMs":173309,"modelName":"glm-4.7"}}